Promising Market Position and Pipeline Advancements Make Nuvation Bio a Strong Buy

TD Cowen analyst Yaron Werber has maintained their bullish stance on NUVB stock, giving a Buy rating on April 23.

Yaron Werber has given his Buy rating due to a combination of factors that highlight Nuvation Bio’s promising position in the market. The company is advancing towards the approval of taletrectinib for ROS1+ NSCLC, with all necessary FDA inspections completed, and no advisory committee expected due to its breakthrough designation. This positions the company well for a U.S. launch in mid-2025, presenting a significant opportunity for investors as there are no financing risks.
Additionally, Nuvation Bio is preparing for the release of Phase 2 data for safusidenib in low-grade glioma, which is anticipated to differentiate it from existing treatments. The upcoming data will guide the design of pivotal studies, further strengthening the company’s pipeline. The combination of these developments, alongside the absence of financial overhangs, makes the stock an attractive investment at its current valuation.

Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Ascendis Pharma, and Argenx Se. According to TipRanks, Werber has an average return of 7.6% and a 49.51% success rate on recommended stocks.

In another report released on April 23, Citizens JMP also initiated coverage with a Buy rating on the stock with a $6.00 price target.